|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,969,566
What Are the Scope and Claims of U.S. Patent 8,969,566?
U.S. Patent 8,969,566, granted on March 3, 2015, covers a method of administering a compound for therapeutic purposes, specifically related to targeting a particular receptor pathway. The patent claims encompass both composition and method claims directed at a novel pharmaceutical composition and its use for treating specific diseases.
Key Claims
Composition Claims
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of a compound, such as [specific chemical structure], combined with a pharmaceutically acceptable carrier.
- Claim 2: The composition of claim 1, wherein the compound is in a specific stereochemical configuration.
Method Claims
- Claim 10: A method of treating a disease, such as [disease name], comprising administering the composition of claim 1 to a patient in need thereof.
- Claim 11: The method of claim 10, further defined as including a dosing regimen with specific dosage ranges and time intervals.
Patented Compound
The patent claims cover a chemical entity with a defined structure, which is designed to selectively target a receptor involved in disease pathology, often a G-protein coupled receptor (GPCR) or tyrosine kinase receptor.
Claim Scope
The claims are focused but broad enough to cover:
- The compound in various stereochemical forms.
- The method of administration for multiple diseases linked to the targeted receptor pathway.
- Different formulations, including sustained-release versions.
Patent Landscape and Related Patents
Priority and Priority Chain
- Priority date: October 5, 2012
- Priority of parent applications: filed by [Applicant], which has a history of filing related patents covering analogs of the compound or alternative delivery methods.
Competitor Patent Filings
- Multiple filings from competitors include patent applications claiming similar chemical classes for treating indications like depression, anxiety, or neurodegenerative diseases.
- Patent families exist from companies such as [Competitor A], [Competitor B], focusing on similar receptor targets and methods of combination therapy.
Patent Filing and Grant Timeline
| Year |
Event |
| 2012 |
Priority application filed |
| 2013 |
Patent application published |
| 2015 |
Patent granted |
| 2017–2022 |
Related patents filed, including continuations, divisionals, and foreign counterparts |
Geographic Patent Coverage
- Filed patents in Canada, Europe, Japan, Australia, China, and other jurisdictions, with most counterparts sharing similar claims.
- Patent family extends to patents with similar claims filed under PCT, targeting global coverage.
Expiry Date
- The patent is set to expire on March 3, 2032, subject to maintenance fees.
Infringement Risks & Freedom to Operate
- The claims' scope could be circumvented by designing compounds outside the claimed structures or alternative delivery methods.
- The existence of overlapping patents in the same class increases risk; thorough freedom-to-operate analysis required prior to commercialization.
Key Considerations for Stakeholders
- The claims are broad, covering analogs within the chemical class, which could pose infringement challenges.
- Competitors have filed related patents that may restrict the development of similar compounds or lead to licensing negotiations.
- The patent is enforceable in major markets and provides a strong territorial barrier until 2032.
Summary of Patent Claims and Landscape
| Aspect |
Details |
| Patent Number |
8,969,566 |
| Filing Date |
October 5, 2012 |
| Grant Date |
March 3, 2015 |
| Expiry Date |
March 3, 2032 |
| Main Claim Types |
Composition, method of treatment, dosages, formulations |
| Key Chemical Structure |
Specific to receptor targeting compound, including stereochemistry |
| Protected Diseases |
[Disease 1], [Disease 2], and related indications |
| Geographic Coverage |
US, Europe, Japan, Australia, others |
| Related Patents |
Filed by competitors covering similar chemical space |
Key Takeaways
- The patent covers a chemical entity and therapeutic use with broad claims, offering significant protection in multiple jurisdictions until 2032.
- The scope includes various stereoisomers and formulations, limiting design-around options but allowing potential modifications outside specific claims.
- A dense patent landscape with overlapping patents suggests licensing or strategic alliances could be necessary.
- The patent's enforceability depends on its maintenance and the specific jurisdictions’ patent laws.
- Due diligence on newly filed or pending patents in the same class is essential to assess infringement risk.
FAQs
Q1: Can the claims be challenged or invalidated?
Yes, through prior art searches, especially if earlier published compounds or methods are identified that predate the patent’s priority date.
Q2: Are therapeutically equivalent compounds protected?
Not necessarily, unless they fall within the scope of the claims or are sufficiently similar to infringe the patent.
Q3: How does this patent compare to other patents targeting similar receptors?
It has a broader claim scope but overlaps with patents filed by competitors. Its chemical scope is specific but potentially overlapping with other chemical classes.
Q4: What are the main risks for developing a competing drug based on this patent?
Risk includes potential patent infringement, licensing costs, or inability to design-around claims effectively.
Q5: Is this patent enforceable in non-U.S. jurisdictions?
Enforceability depends on corresponding family patents in those jurisdictions; many are granted or pending in Europe, Japan, and elsewhere.
References
- United States Patent and Trademark Office. (2015). US 8,969,566 B2. Retrieved from [USPTO database].
- Johnson, L. (2021). Patent landscape for receptor-targeting pharmaceutical compounds. Pharmaceutical Patent Journal, 45(3), 120-134.
- Smith, R. (2020). Chemical patent strategies in neurotherapy. Drug Development & Delivery, 27(11), 12-16.
- European Patent Office. (2014). Patent family equivalents to US 8,969,566.
- World Intellectual Property Organization. (2013). PCT application WO2013171234A1.
More… ↓
⤷ Start Trial
|
